We are international

Sydney 2005: Antagonist Anti-CD40 antibody CHIR-12.12 Causes Tumour Regr. & Prolongs Survival in MM
By Li Long
Dr. Li Long continued the MAB discussion with his presentation on the antagonist Anti-CD40 antibody CHIR-12.12. CD40 is expressed in all types of malignant B cells as well as dendritic cells, monocytes, and macrophages. CD40 in both normal and primary malignant B cells affects cell survival and proliferation. In MM, CD40 is expressed in over 80% of patients in variable levels. CD40 is stimulated by CD40 ligand (L), which prolongs survival of MM cells. CHIR-12 is a fully humanized antibody of IgG1. CHIR-12 potently inhibits CD40 L-induced human B lymphocytic proliferation. Data was shared from a pre-clinical study in a mouse model. CHIR-12 was shown to reduce cell proliferation, and induce cell death. CHIR-12 also exhibited significant anti-myeloma activity in bortezomib-insensitive in the mouse model. Dr. Long noted that CHIR-12 is currently in Phase 1 clinical trial for chronic lymphocytic leukemia (CLL) and a Phase 1 trial for MM is planned for 2005.

Back to session summary

 related articles